Get the Stockscreener App
4.83
4.55%
-0.23
After Hours:
4.88
0.05
+1.04%
Cingulate Inc stock is traded at $4.83, with a volume of 146.05K.
It is down -4.55% in the last 24 hours and down -17.72% over the past month.
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
See More
Previous Close:
$5.06
Open:
$5.01
24h Volume:
146.05K
Relative Volume:
0.81
Market Cap:
$70.24M
Revenue:
-
Net Income/Loss:
$-27.71M
P/E Ratio:
-1.1334
EPS:
-4.2615
Net Cash Flow:
$-19.77M
1W Performance:
-7.82%
1M Performance:
-17.72%
6M Performance:
-24.06%
1Y Performance:
+27.44%
1-Day Range:
$4.80
$5.12
1-Week Range:
$4.80
$5.48
52-Week Range:
$3.16
$11.89
Cingulate Inc Stock (CING) Company Profile
Name
Cingulate Inc
Sector
Industry
Phone
(913) 942-2300
Address
1901 W. 47TH PLACE, KANSAS CITY
Compare CING vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CING
Cingulate Inc
|
4.83 | 70.24M | 0 | -27.71M | -19.77M | -4.2615 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cingulate Inc Stock (CING) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | ROTH MKM | Buy |
| Dec-22-23 | Downgrade | Laidlaw | Buy → Hold |
Cingulate Inc Stock (CING) Latest News
Cingulate Stock Price Forecast. Should You Buy CING? - StockInvest.us
Shane Schaffer, Cingulate Chairman & CEO to Present “SMART - GlobeNewswire
Title: Cingulate Inc. (CING) Edges Lower to $5.09, Holding Above Key Support as Traders Eye $5.34 ResistanceEase of Movement - careplusvn.com
Cingulate Inc. Warrants (CINGW) Peer Comparison – Compare with Others - Value Research
Why Is CING Stock Jumping Over 4% In Overnight Trading? - Stocktwits
CING Q2 2026 Earnings: Narrower Loss Delivers 29.4% EPS SurpriseRevenue Report - vinanet.vn
Cingulate Inc. Warrants (CINGW) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Cingulate Inc. Warrants (CINGW) Key Financial Ratios – Valuation, Profitability & More - Value Research
Cingulate Inc. Warrants (CINGW) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Analysts Offer Insights on Healthcare Companies: Eloxx Pharmaceuticals (ELOX), Cingulate Inc (CING) and Agilon Health (AGL) - The Globe and Mail
Cingulate (CING) Results Check: EPS Misses Its Estimate in the Current Update; After Earnings: Shares Close 3.35% Higher for the Current SessionEarnings Trend Analysis - dars.gov.et
Cingulate (CING) Results Review: Reported EPS Misses Expectations; Latest Reaction: Shares Close 4.13% Higher for the Current SessionBasic EPS Analysis - vinanet.vn
Zacks Research Has Bullish Outlook for Cingulate Q3 Earnings - MarketBeat
Ascendiant Capital Markets Cuts Cingulate (NASDAQ:CING) Price Target to $44.00 - MarketBeat
CINGULATE INC : ASCENDIANT CAPITAL MARKETS CUTS TARGET PRICE TO $44 FROM $52 - Bitget
Cingulate (CING) Results at a Glance: The EPS Result Is Below Expectation in Latest Trading; Market Reaction: The Market Price Moves 1.35% Higher in the Current UpdateEarnings Manipulation Risk - careplusvn.com
Cingulate (CINGW) Levels: Finishes 26.88% Up at $0.01 at the Close; Trading Range: the Price Remains Bounded by the Supplied Support and Resistance at the CloseValue Area Low - vinanet.vn
Cingulate (CING) Quarterly Results: EPS Comes in Below Forecast; Closing Move: Shares Close 1.73% Higher in Latest TradingSurprise Factor Analysis - vinanet.vn
CING: Second Quarter Results - Yahoo Finance
Cingulate (CING) Results Breakdown: EPS Comes in Below Forecast at the Close; Market Read: The Share Price Sheds 0.19% in the Latest SessionEarnings Season Review - dars.gov.et
Cingulate CEO Dr. Shane J. Schaffer: Why a Child's ADHD Diagnosis Often Reveals ADHD in a Parent - inkl
CING Q1 2026 Earnings: Wider-Than-Expected Loss of -$0.95 Per Share as Clinical-Stage Costs Persist - vinanet.vn
Cingulate (NASDAQ:CING) Upgraded by Wall Street Zen to "Sell" Rating - MarketBeat
Cingulate (NASDAQ:CING) Posts Quarterly Earnings Results - MarketBeat
Form 8K Cingulate Inc For: 13 August By Investing.com - Investing.com Australia
Form 8K Cingulate Inc For: 13 August - Investing.com Nigeria
Cingulate reports Q2 loss, plans FDA resubmission for ADHD drug By Investing.com - Investing.com Canada
Cingulate reports Q2 loss, plans FDA resubmission for ADHD drug - Investing.com Nigeria
Cingulate Inc. Q2 2026: Revenue $0 Net loss $5.87M — 10-Q Summary - TradingView
Cingulate Reports $5.9 Million Second-Quarter Loss, $28.4 Million Cash - Quiver Quantitative
Cingulate Reports Q2 2026 Results: $28.4M Cash; Net Loss $5.9M for Quarter - TradingView
Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness - marketscreener.com
Cingulate Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Cingulate Inc. (CING) Debt 2025 - Stock Titan
Cingulate Inc. Warrants (CINGW) Rise 9.72% to $0.01 as Support and Resistance AlignSmall Cap Breakouts - dars.gov.et
Cingulate publishes pharmacokinetic study on ADHD drug candidate - Investing.com
Cingulate publishes pharmacokinetic study on ADHD drug candidate By Investing.com - Investing.com Australia
Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301’s Differentiated Pharmacokinetic Profile - GlobeNewswire
CING Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Cingulate (CING) Expected to Announce Earnings on Tuesday - MarketBeat
Cingulate Inc. (CING) Dips 1.69% to $5.25: Support and Resistance Levels in SpotlightBullish Percent Index - dars.gov.et
Cingulate Inc. Revenue Breakdown – BOATS:CINGW - TradingView
Cingulate Inc (CING) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cingulate Inc (CING) Stock News Today - TradingKey
Cingulate Inc Stock (CING) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):